Merck ditches biosimilar Lantus, but will that ease the path for Mylan’s rival insulin product?

12th October 2018 Uncategorised 0

The basal insulin market is so lousy with pricing pressures—and the products are so costly to make—that Merck has canceled its deal with Samsung Bioepis for a Lantus biosimilar. But even with Merck out of the game, it’s unclear whether Mylan and partner Biocon can deal with those challenges.

More: Merck ditches biosimilar Lantus, but will that ease the path for Mylan’s rival insulin product?
Source: fierce